Kitajima I
Department of Laboratory Medicine, Kagoshima University.
Rinsho Ketsueki. 1995 Apr;36(4):303-7.
Thrombin, a key enzyme in the hemostatic pathway, also has various effects on the function of human platelet, endothelial cells (HUVEC) and vascular smooth muscle cells (VSMC). A thrombin receptor (TR) has been cloned and is thought to mediate a variety of thrombin-induced responses. The post-receptor signals are mediated by several protein kinases responsible for NF-kappa B activation, and most thrombin-inducible genes have the kappa B sequence in the regulatory elements. TR stimulation resulted in a biphasic activation of NF-kappa B and the late phase of which required new NF-kappa B synthesis. We showed that the antisense oligodeoxynucleotides (ODNs) of NF-kappa B have a marked inhibitory effect on thrombin-induced cellular responses. Furthermore, E5510, a compound with anti-platelet activity preferentially inhibited the thrombin-inducible NF-kappa B activation. Therapeutic potential of inhibition of TR-NF-kappa B activation signaling for treatment with thrombotic disease is also indicated.
凝血酶是止血途径中的关键酶,对人血小板、内皮细胞(人脐静脉内皮细胞)和血管平滑肌细胞的功能也有多种影响。一种凝血酶受体(TR)已被克隆,被认为介导多种凝血酶诱导的反应。受体后信号由负责激活核因子κB的几种蛋白激酶介导,大多数凝血酶诱导基因在调控元件中具有κB序列。TR刺激导致核因子κB的双相激活,其后期需要新的核因子κB合成。我们发现核因子κB的反义寡脱氧核苷酸(ODN)对凝血酶诱导的细胞反应有显著抑制作用。此外,具有抗血小板活性的化合物E5510优先抑制凝血酶诱导的核因子κB激活。抑制TR-核因子κB激活信号通路治疗血栓性疾病的潜在治疗价值也得到了体现。